linjc16/ctgov huggingface dataset:
Effect of Cataract Hyperemulsification Surgery on Meibomian Gland Morphology and Function

Study Overview
=================
Brief Summary
-----------------
50 participants at Eye Hospital of Wenzhou Medical University during August, 2017 to July, 2020 will be enrolled in this study. To study the effect of cataract supermammary surgery on the morphology and function of meibomian glands

Official Title
-----------------
Effect of Cataract Hyperemulsification Surgery on Meibomian Gland Morphology and Function

Conditions
-----------------
Meibomian Gland Dysfunction

Intervention / Treatment
-----------------
* Procedure: cataract surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previously untreated patients with xerophthalmia Undergoing cataract hyperemulsification surgery Exclusion Criteria: No history of ocular surgery and trauma Any eye diseases except xerophthalmia No treated for xerophthalmia before Successful completion of follow-ups

Ages Eligible for Study
-----------------
Minimum Age: 38 Years
Maximum Age: 87 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Eyes for cataract surgery<br>Eyes for cataract surgery | Procedure: cataract surgery<br>* Eyes for cataract surgery<br>|
| Eyes without cataract surgery<br>Eyes without cataract surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OSDI scale survey | OSDI scale survey | 08/2017 to 07/2020 | 
| tear meniscus height（mm） | tear meniscus height（mm） | 08/2017 to 07/2020 | 
| first tear film rupture time（s） | first tear film rupture time（s） | 08/2017 to 07/2020 | 
| average tear film rupture time（s） | average tear film rupture time（s） | 08/2017 to 07/2020 | 
| the range of meibomian gland missing（%） | the range of meibomian gland missing（%） | 08/2017 to 07/2020 | 
| meibomian gland average diameter (mm) | meibomian gland average diameter (mm) | 08/2017 to 07/2020 | 
| meibomian gland length (mm) | meibomian gland length (mm) | 08/2017 to 07/2020 | 
| meibomian gland area (mm^2) | meibomian gland area (mm^2) | 08/2017 to 07/2020 | 
| meibomian gland deformation coefficient | meibomian gland deformation coefficient | 08/2017 to 07/2020 | 
| meibomian gland total proportion of glands (%) | meibomian gland total proportion of glands (%) | 08/2017 to 07/2020 | 
| meibomian gland imaging value | meibomian gland imaging value | 08/2017 to 07/2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
meibomian gland, cataract surgery
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

Study Overview
=================
Brief Summary
-----------------
This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for the later phase study.

Detailed Description
-----------------
A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250 mg, 375 mg and 500 mg) administered twice daily for 16 weeks, on top of aspirin (325 mg, qd) in men and women with non valvular atrial fibrillation at a low or intermediate risk for stroke

Official Title
-----------------
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke

Conditions
-----------------
Fibrillation, Atrial, Atrial Fibrillation

Intervention / Treatment
-----------------
* Drug: SB424323


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with non valvular atrial fibrillation and any of the following: </= 60 years old with no heart disease. 60 years old with heart disease but no risk factors. >/=60 years old and </=75 years old with no risk factors and no heart disease. Must be able to take aspirin. Exclusion Criteria: Previous heart attack or stroke. History of high blood pressure, diabetes or a prior blood clot. Liver or kidney disease. Need for anti-thrombotic or anti-platelet drugs. Need for cardiovascular medicines.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: SB424323|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between anti IIa (a biomarker)and the dose of SB424323. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood levels of SB424323 during the study. Number of strokes, transient ischemic attacks or systemic embolism during the study. Changes in laboratory tests during the study. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non valvular atrial fibrillation, stroke, aspirin
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Ovarian Failure

Study Overview
=================
Brief Summary
-----------------
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Ovarian Failure

Detailed Description
-----------------
This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of Ovarian Failure. Patients will receive a single intravenous infusion of UC-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy. For patients with more severe disease an autologous Effector cells (activated lymphocytes) treatment will be utilized created from the patient's own cells obtained by apheresis.

Official Title
-----------------
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Ovarian Failure

Conditions
-----------------
Ovarian Failure

Intervention / Treatment
-----------------
* Biological: AlloRx


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Ovarian Failure Understanding and willingness to sign a written informed consent document Exclusion Criteria: Active infection Active cancer Chronic multisystem organ failure Pregnancy Clinically significant Abnormalities on pre-treatment laboratory evaluation Medical condition that would (based on the opinion of the investigator) compromise patient's safety. Continued drug abuse Previous organ transplant Hypersensitivity to sulfur
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Group (AlloRx)<br>Single intravenous infusion of 100 million cells | Biological: AlloRx<br>* cultured allogeneic adult umbilical cord derived mesenchymal stem cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (adverse events) | Clinical monitoring of possible adverse events or complications | Four year follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ovarian Failure, stem cell treatment
Video-assisted Thoracoscopic Thymectomy Versus Subxiphoid Procedure

Study Overview
=================
Brief Summary
-----------------
Surgerys used in thymectomy for myasthenia gravis and anterior mediastinal tumours have become much less invasive in recent years. In our study, the surgical technique which resected the thymus below the xiphoid process and the technique which was regarded as conventional video- assisted thoracoscopic surgery (VATS) thymectomy was compared.

Official Title
-----------------
Video-assisted Thoracoscopic Thymectomy Versus Subxiphoid Thymectomy: Short- Term and Long- Term Results

Conditions
-----------------
Thymectomy

Intervention / Treatment
-----------------
* Procedure: Subxiphoid surgery procedure
* Procedure: VATS surgery procedure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Thymoma with or without myasthenia gravis； Generalized myasthenia gravis not sensitive to conservative medicine treatment; Good cardiopulmonary function. Exclusion Criteria: Cardiopulmonary function can't bear surgery; Generalized myasthenia gravis with MuSK(+).

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Subxiphoid group<br>Subxiphoid procedure for thymectomy. | Procedure: Subxiphoid surgery procedure<br>* Subxiphoid procedure for thymectomy<br>|
| Active Comparator: VATS group<br>Video-assisted thoracoscopic thymectomy through chest wall. | Procedure: VATS surgery procedure<br>* VATS procedure for thymectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale of postoperative pain | in score | within 3 days | 
| Operation time | in minutes | one day | 
| The amount of blood loss | in milliliter | one day | 
| Duration of drainage | in days | with 7 days | 
| Duration of hospital stay | in days | with 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete remission rates | Complete remission rates after 5 year follow-up of thymectomy for myasthenia gravis | 5 years | 
| Recurrence rate | Recurrence rate after 5 year follow-up of thymectomy for thymoma | 5 years | 
| Overall survival | Overall survival in rate | within 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Video-assisted thoracoscopic surgery, Subxiphoid approach
An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to show the efficacy of a single dose of PRO-513 for treating subjects suffering moderate pain form a migraine attack, with or without aura. The study is also intended to show the effectiveness of PRO-513 for associated symptoms of nausea, photophobia, and phonophobia due to a migraine attack.

Conditions
-----------------
Migraine, Photophobia, Phonophobia

Intervention / Treatment
-----------------
* Drug: PRO-513


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and Female subjects 18-65 years of age Primary diagnosis of migraine attack with aura or migraine attack without aura Migraine history of averaging at least 1 migraine attack per month but averaging not more than 6 migraine attacks per month over the prior year Female subjects must use an effective form of birth control Listing of additional inclusion criteria are available through the Sponsor Exclusion Criteria: Excluding subjects with a history of other serious events causing secondary headaches Excluding subjects with a current medical condition that could interfere with the overall study intent or affect the absorption, distribution, metabolism, or excretion of the study medication Excluding subjects with a history or current medical condition that could confound the study results or use of a concomitant medication that could interfere with the study drug Listing of additional exclusion criteria are available through the Sponsor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: PRO-513|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aura, Migraine, Photophobia, Phonophobia
Clinical Evaluation of 755nm Alexandrite Laser Versus Nanosecond 755nm Alexandrite

Study Overview
=================
Brief Summary
-----------------
Compare the efficacy of the 755nm Alexandrite laser to the nanosecond 755nm Alexandrite laser for the removal of unwanted tattoos using photographic evaluation and histological findings.

Conditions
-----------------
Tattoos

Intervention / Treatment
-----------------
* Device: 755nm Alexandrite Laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Is a healthy male or female between 18 and 85 years old? Has unwanted non-cosmetic tattoo(s) and wishes to undergo laser treatments Is willing to consent to participate in the study. Is willing to shield the tattoo completely from sun exposure Signs informed consent form Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits. Exclusion Criteria: Subjects who are unwilling to consent to tattoos Subjects mentally ill or incompetent Subjects is unwilling to have photographs taken and used in publications or scientific presentations Subjects who are prisoners Subjects with recent sun exposure and suntan in the area to be treated Allergic tattoos (hypersensitivity to tattoo ink) History of vitiligo or keloidal scarring Tattoos located on the neck or face including cosmetic tattoos Subjects unwilling to tolerate partial removal of the tattoo in this study Infection or skin disease in the area to be treated Subjects who are immunosuppressed (e.g. HIV) Subject is pregnant or nursing Use of oral isotretinoin within past 12 months History of squamous cell carcinoma or melanoma Is allergic to Lidocaine, tetracaine or Xylocaine with epinephrine. Has any other reason determined by the physician to be ineligible to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 755nm Alexandrite Laser<br>755nm Alexandrite Laser | Device: 755nm Alexandrite Laser<br>* 755nm Alexandrite Laser<br>|
| Experimental: Nanosecond 755nm Alexandrite Laser<br>Nanosecond 755nm Alexandrite Laser | Device: 755nm Alexandrite Laser<br>* 755nm Alexandrite Laser<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Photographic Evaluation of Tattoo Clearance |  | up to 3 months post last treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subject biopsy sampling | Histological evaluation of tissue samples pre-treatment and post-treatment | up to 3 months post last treatment |
Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the efficacy and safety of sugammadex in reversing profound neuromuscular block induced by rocuronium in infant patients

Official Title
-----------------
Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study

Conditions
-----------------
Brain Cancer

Intervention / Treatment
-----------------
* Drug: Sugammadex


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients between the ages of 1-12 month, ASA physical status 1-3 who underwent elective brain cancer surgery during general anesthesia were included in the study Exclusion Criteria: younger than 1month or older than 12 months. hepatic or renal failure A history of allergy to study medication

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Sugammadex, Bridion<br>Drug were given intravenously by a anesthesiologist at the end of surgery | Drug: Sugammadex<br> <br> * Other names: Bridion;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The efficacy of sugammadex were assessed by using Train of four (TOF) |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sugammadex, Rocuronium, Infant patients
Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years

Study Overview
=================
Brief Summary
-----------------
The primary objective is to examine the percentage of patients with PTSD who were prescribed an antipsychotic over the past seven years in the VA Network 7 (AL, GA, SC) and compare the percentage on an annual basis. We will also determine the type and dose of antipsychotics received. We hypothesize that there has been a significant increase in antipsychotic use, especially atypical antipsychotics, prescribed for patients with PTSD over the last 7 years

Detailed Description
-----------------
This study is a retrospective electronic review of the VISN 7 Data Warehouse to determine what have been the emerging trends in prescriptions of atypical antipsychotic medications over the past seven years for the treatment of posttraumatic stress disorder (PTSD) in the VA This study is a retrospective electronic review of patients of the VISN 7 Data Warehouse of patients with a diagnosis of PTSD treated with antipsychotics as monotherapy or adjunctive therapy at a VA Medical Center or VA clinic in VISN 7 (GA, SC, and AL). The data will be retrieved from a computerized list of patients treated in VA VISN 7 for PTSD from 1998-2005 and cross-referenced with the electronic pharmacy file for having received a prescription of an antipsychotic medication. No personal identifiers will be collected. The data will then be examined to determine what type of antipsychotics were prescribed and the dose and duration of the antipsychotics. In addition, demographics and clinical characteristics available through the Data Warehouse will be collected.

Official Title
-----------------
Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years

Conditions
-----------------
PTSD, Post-Traumatic Stress Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients, any race or ethnic origin at least 19 years of age. Patients with a diagnosis of PTSD Treated with an antipsychotic as a monotherapy or adjunctive therapy Patient must have been seen at a VA medical center or clinic within VISN 7 during the study period. Exclusion Criteria: Patients not diagnosed with PTSD Not treated with an antipsychotic as a monotherapy or adjunctive therapy Patients outside of Network 7 Patients with a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antipsychotics, PTSD, Post Traumatic Stress Disorder, monotherapy, adjunct therapy